Principles and clinical management of alpha 1-antitrypsin deficiency.
Alpha 1-antitrypsin (alpha 1-AT) deficiency can cause a lung disease that, until a few years ago, has proved fatal to all patients diagnosed with this disease. This deficiency can now be treated with alpha 1-proteinase inhibitor, a protein derived from human plasma and delivered via intravenous infusion. Infusion therapy for alpha 1-AT deficiency can be delivered in the hospital or home environments. This article discusses the pathophysiology of alpha 1-AT deficiency and outlines nursing considerations for the intravenous clinician who is administering this therapy.